MicroPort® MedBot™’s Toumai ® Robot Receives Market Approval in Brazil

São Paulo, Brazil, 22 December 2024 – MicroPort^® MedBot™ recently announced that its Toumai^® Laparoscopic Surgical Robot (Toumai^® Robot) has received market approval from Brazil’s National Health Surveillance Agency (ANVISA). This marks a significant milestone in advancing remote surgical technology and expanding access to robotic-assisted surgery in Latin America.

The launch ceremony took place on December 8 in São Paulo, gathering over 70 renowned surgical experts from around the world. Attendees witnessed a groundbreaking remote animal surgery, conducted from Brazil to the United States using Toumai^® technology. The event also included discussion on how Toumai^® and remote surgical technologies are poised to revolutionized the surgical robotics market and transform surgical practices across Latin America. 

MicroPort^® MedBot™ has achieved several global firsts in robotic-assisted surgery:

• It developed the world’s first force-sensing component for laparoscopic surgery robots, addressing the challenge of tactile feedback during robotic procedures.
• In the endoscopy field, MedBot™ introduced the world’s first multimodal real-time fusion fluorescence 3D electronic thoraco-abdominal endoscope, specifically designed for laparoscopic surgery robots, which has already been approved for commercial use.

William Krinickas, Vice President of MedBot™ Latin America, stated: “The Toumai ^® robot sets a new benchmark for healthcare standards, delivering more precise and effectiveness in surgical treatments. Its entry into the Latin American market represents a critical step forward in providing patients with safe, cutting-edge, and reliable treatment options.”

About MicroPort^® MedBot™   

Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort^® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort^®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort^® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.

More information is available at: www.medbotsurgical.com/en